1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes
    Meeting Abstract

    Hahn, N. M.; Picus, J.; Bambury, R. M.; Pal, S. K.; Hart, L. L.; Grivas, P.; Milowsky, M. I.; Alva, A. S.; Sonpavde, G.; Mortazavi, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study)
    Meeting Abstract

    Fleisher, M.; Danila, D. C.; Fizazi, K.; Hirmand, M.; Selby, B.; Phung, D.; de Bono, J. S.; Scher, H. I.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591
    Meeting Abstract

    Feldman, J. L.; Morris, M. J.; Martinez, D. F.; Tagawa, S. T.; Nanus, D. M.; Solomon, S. B.; Carrasquillo, J. A.; Reuter, V. E.; Lewis, J. S.; O'Donoghue, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT)
    Meeting Abstract

    Feldman, D. R.; Bagrodia, A.; Lee, B.; Lee, W.; Al-Ahmadie, H.; Cha, E. K.; Sfakianos, J.; Iyer, G.; Zabor, E. C.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Crossover in oncology clinical trials
    Meeting Abstract

    Diaz, J.; Sternberg, C. N.; Mehmud, F.; Delea, T. E.; Latimer, N.; Bartlett-Pandite, A. N.; Motzer, R.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prognostic value of genomic signatures in metastatic clear cell renal cell carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data
    Meeting Abstract

    de Velasco, G.; Fay, A. P.; Culhane, A.; Hakimi, A. A.; Voss, M. H.; Tannir, N. M.; Tamboli, P.; Appleman, L. J.; Bellmunt, J.; Rathmell, K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Fleisher, M.; Carrasquillo, J. A.; Gilbert, H.; Morris, M. J.; Bellomo, L. P.; Hendrikx, P. J.; Szafer-Glusman, E.; Herkal, A.; Patel, C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer
    Meeting Abstract

    Choueiri, T. K.; Hahn, N. M.; Alva, A. S.; Lauer, R. C.; Dreicer, R.; Picus, J.; Pili, R.; Balar, A. V.; Sonpavde, G.; Hoffman-Censits, J. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer
    Meeting Abstract

    Bellmunt, J.; Sonpavde, G.; De Wit, R.; Choueiri, T. K.; Siefker-Radtke, A. O.; Plimack, E. R.; Lewis, N. M.; Brown, H.; Mai, Y. B.; Gause, C. K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save